Life Sciences

Dr. Payel Datta earned her Ph.D. in Life Sciences from Rensselaer Polytechnic Institute (RPI, NY), and her Ph.D. work focused on "Metabolic engineering mammalian cells for the production of value-added-biomolecules". Her postdoctoral work at Albany Medical College focused on developing and utilizing a 3D cell-based assay. Dr. Datta's work at Heparin Applied Research Center (start-up Industry-RPI, NY) focused on process development, scale-up, and tech transfer of value-added products (e.g., enzymes, small molecules, anticoagulant drug heparin, probiotic bacteria). In addition, her research focused on drug efficacy and toxicity studies. Dr. Datta has coauthored a book chapter in the “Encyclopedia of Microbiology”, numerous publications in peer-reviewed journals, presented work at conferences, and authored technical documents. Dr. Datta is highly motivated to harness her expertise and knowledge in teaching, research, and workforce development.

Education

• PhD, Biology, Rensselaer Polytechnic Institute, Troy, NY, 2013

Academic Courses Taught at ACPHS (2021-Present)

• Mammalian Cell Culture (BIO331 and BIO631G)
• Microbial Fermentation (BIO348 and BIO648G)
• Biopharmaceutical Capstone (BIO675G)
• Downstream Processing of Biopharmaceutical Products (PSC320 and PSC620G)
• Regulatory Science (PSC646G)
• Microbes and Me (BIO105)

Workforce Development and Training Programs at CBET (2021-Present)

• Principles of Biomanufacturing
• Mammalian Cell Culture: From cell bank to bioreactor
• NIIMBL eXperience at ACPHS
• FDA mRNA Training Program at ACPHS

Current Research Interests
The research in our lab focuses on cell biotechnology, bioprocessing, and industrial microbiology. Specifically, the research aims to (1) evaluate how bioprocessing parameters impact cell growth, metabolic profile, and productivity and (2) harness the knowledge towards optimizing bioprocessing parameters to achieve robust cell culture growth, cell line stability, and maximize product yields. In parallel, a second aim of the lab is drug discovery research. Specifically, the lab focuses on developing cell-based and biomolecular interaction assays to evaluate biomolecules' biological activity and potency.

Professional Service

• National Science Foundation (NSF) Grant Reviewer/Panelist for the Centers of Research Excellence in Science and Technology (CREST Centers, 2024)
• National Science Foundation (NSF) Grant Reviewer/Panelist, Division of Chemical, Bioengineering, Environmental and Transport Systems (2024).

Journal Review

• Biomolecules
• Biotechnology and Bioengineering
• Cells
• Genes
• Microbial Cell Factories
• Process Biochemistry

Book Chapter

• Industrial production of glycosaminoglycans. P. Datta, R. J. Linhardt, S. T. Sharfstein. In Encyclopedia Of Microbiology  https://www.sciencedirect.com/science/article/pii/B9780128096338122241

Patent Applications

• Biosynthetic Heparin, US Patent 11,591,628

Selected List of Publications

*denotes undergraduate and graduate students

1. Stipulations of Cell and Gene Therapy and the Ties to Biomanufacturing. J. Allisha*, J. Das*, T. Dunnigan*, S.T. Sharfstein and P. Datta. Biotechnology Progress (accepted, November/December 2024, in press)
2. Inhibition of sulfated glycans on the binding of dengue virus envelope protein to heparin. J. Yang, P. Datta, K. Xia, V.H. Pomin, C. Wang, M. Qiao, R.J. Linhardt, J. S. Dordick, and F. Zhang. Glycoconjugate Journal (accepted, December 2024)
3. Synthesis of bioengineered heparin chemically and biologically similar to porcine-derived products and convertible to low MW heparin. PNAS (2024). https://doi.org/10.1073/pnas.2315586121  
4. Anti-SARS-CoV-2 activity of rhamnan sulfate from Monostroma nitidum. Y. Song, P. He, A. L. Rodrigues, P. Datta, R. Tandon, J. T. Bates, M. Bierdeman, C. Chen, J. S. Dordick, F. Zhang, R. J. Linhardt, Marine Drugs. pubmed.ncbi.nlm.nih.gov/34940684/
5. An ‘omics approach towards CHO cell engineering. P. Datta, R. J. Linhardt, S. T. Sharfstein. Biotechnology and Bioengineering. pubmed.ncbi.nlm.nih.gov/23322664/
6. Evaluating heparin products for heparin-induced thrombocytopenia using Surface Plasmon Resonance. F. Zhang, P. Datta, J. S. Dordick, R. J. Linhardt, Journal of Pharmaceutical Sciences. pubmed.ncbi.nlm.nih.gov/31705871/
7. Platelet factor 4 polyanion immune complexes: Heparin induced thrombocytopenia and vaccine-induced immune thrombotic thrombocytopenia. P. Datta, F. Zhang, J. S. Dordick, R. J. Linhardt, Thrombosis Journal. pubmed.ncbi.nlm.nih.gov/34526009/
8. Complete biosynthesis of a sulfated chondroitin in Escherichia coli. A. Badri, A. Williams, A. Awofiranye, P. Datta, K. Xia, W. He, K. Fraser, J. S. Dordick, R. J. Linhardt, M.A.G. Koffas, Nature Communication. nature.com/articles/s41467-021-21692-5
9. Heparosan chain characterization: sequential depolymerization of E. coli K5 heparosan by a bacterial eliminase heparin lyase III and a bacterial hydrolase heparanase Bp to prepare defined oligomers. P. Datta, L. Yan, A. Awofiranye, J. S. Dordick, R. J. Linhardt, Biotechnology Journal. pubmed.ncbi.nlm.nih.gov/33006278/
10. High cell density fermentation of probiotic E. coli Nissle 1917 towards heparosan production, characterization, and modifications. P. Datta, L. Fu, P. Brodfuerer, J. S. Dordick, R. J. Linhardt, Applied Microbiology and Biotechnology. https://pubmed.ncbi.nlm.nih.gov/33481068/
11. Enzymatic generation of highly anticoagulant bovine intestinal heparin. L. Fu, K. Li, D. Mori, M. Hirakane, L. Lin, N. Grover, P. Datta, Y. Yu, J. Zhao, F. Zhang, M. Yalcin, S. Mousa, J. S. Dordick, R. J. Linhardt, Journal of Medicinal Chemistry. pubmed.ncbi.nlm.nih.gov/28972371/
12. Expression of enzymes for 3'-phosphoadenosine-5'-phosphosulfate (PAPS) biosynthesis and their preparation for PAPS synthesis and regeneration. P. Datta, L. Fu, W. He, M. A. G. Koffas, J. S. Dordick, R. J. Linhardt, Applied Microbiology and Biotechnology. https://pubmed.ncbi.nlm.nih.gov/32601738/
13. Optimization of bioprocess conditions improves production of a CHO cell-derived, bioengineered heparin. J. Y. Baik, H. Dahodwala, E. Oduah, L. Talman, T. R. Gemmill, L. Gasimli, P. Datta, B. Yang, G. Li, F. Zhang, L. Li, R. J. Linhardt, A. M. Campbell, S. F. Gorfien, S. T. Sharfstein, Biotechnology Journal. pubmed.ncbi.nlm.nih.gov/26037948/
14. Microarray platform affords improved product analysis in mammalian cell growth studies. P. Datta, L. Meli, L. Li, N. Migliore, E. Schaefer, S. T. Sharfstein, J. S. Dordick, R. J. Linhardt, Biotechnology Journal. pubmed.ncbi.nlm.nih.gov/24227746/
15. Modulation of heparan sulfate biosynthesis by sodium butyrate in recombinant CHO cells. P. Datta, B. Yang, R. J. Linhardt, S. T. Sharfstein, Cytotechnology. https://pubmed.ncbi.nlm.nih.gov/24468831/
16. Bioengineered Chinese hamster ovary cells with Golgi-targeted 3-O-sulfotransferase-1 biosynthesize heparan sulfate with an antithrombin-binding site. P. Datta, G. Li, B. Yang, X. Zhao, J. Y. Baik, T. R. Gemmill, S. T. Sharfstein, R. J. Linhardt, Journal of Biological Chemistry. pubmed.ncbi.nlm.nih.gov/24247246/
17. Bioengineering murine mastocytoma cells to produce anticoagulant heparin. L. Gasimli, C. A. Glass, P. Datta, B. Yang, G. Li, T. R. Gemmill, J. Y. Baik, S. T. Sharfstein, J. D. Esko, R. J. Linhardt, Glycobiology. pubmed.ncbi.nlm.nih.gov/24326668/

Selected Lists of Abstracts and Presentations

*denotes undergraduate and graduate students

1. The stipulations of gene therapy and ties to biomanufacturing. J. Allisha*, J. Das*, T. Dunnigan* and P. Datta. 2024 Regeneron Capital Region STEM Poster Showcase. April 2024
2. Workflow for an adalimumab-producing CHO cell line: cell growth, glucose consumption, and monoclonal antibody purification. E. Nelson*, K. Li*, M. Dean*, and P. Datta. 2024 Regeneron Capital Region STEM Poster Showcase. April 2024
3. GFP Expression and Purification from Suspension-adapted HEK293 Cells: A Streamlined Workflow for Recombinant Plasmid Purification, Transfection, and GFP Recovery. R. Sahm*, S. Sheppard*, H. Swint*, and P. Datta. 2024 Regeneron Capital Region STEM Poster Showcase. April 2024
4. A review of quality regulation guidelines and quality assurance in the biomanufacturing industry. H. Swint*, and P. Datta. 2024 Regeneron Capital Region STEM Poster Showcase. April 2024
5. Development Towards a Cell-Based High-Throughput Platform for Unveiling Cell-Health Modulators. V. Carrillo*, H. Swint*, R. Sahm*, J. Das*, and P. Datta. 2024 Regeneron Capital Region STEM Poster Showcase. April 2024 6.
6. Establishing the workflow for monoclonal antibody production and analysis. S. Sheppard*, A. Boni*, J. Goetz*, and P. Datta. 2023 ENYSCASM Trainee Symposium. American Society for Microbiology (ASM) Eastern New York Student Chapter (ENYSCASM). April 2023
7. Characterization and development of seed train for CHO cells: from small scale to bioreactor. J. Uzzell* and P. Datta. 2022 ENYSCASM Trainee Symposium. American Society for Microbiology (ASM) Eastern New York Student Chapter (ENYSCASM). April 2022 8.
8. Production and analysis of monoclonal antibody from a Hybridoma cell line. A. R. Boni* and P. Datta. 2022 ENYSCASM Trainee Symposium. American Society for Microbiology (ASM) Eastern New York Student Chapter (ENYSCASM). April 2022
9. Optimization of a bioprocess for production of a non-protein biopharmaceutical: Production of a bioengineered heparin. S. T. Sharfstein, J. Y. Baik, L. Talman, E. Oduah, B. Yang, G. Li, F. Zhang, P. Datta, R. J. Linhardt. Book of Abstracts 247th American Chemical Society National Meeting and Exposition. 2014
10. Cell engineering heparin and heparan sulfate pathway in mammalian cell line. P. Datta, B. Yang, L. Gasimli, J. Y.Baik, J. D. Esko, R. J. Linhardt, S. T. Sharfstein. National Meeting of the American Chemical Society, New Orleans, LA. April 2013